- Home
- EONR vs PPBT Comparison
EONR vs PPBT Comparison
Compare EONR & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EONR
- PPBT
- Stock Information
- Founded
- EONR 2017
- PPBT 2010
- Country
- EONR United States
- PPBT Israel
- Employees
- EONR N/A
- PPBT N/A
- Industry
- EONR
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- EONR
- PPBT Health Care
- Exchange
- EONR NYSE
- PPBT Nasdaq
- Market Cap
- EONR 7.8M
- PPBT 6.5M
- IPO Year
- EONR N/A
- PPBT N/A
- Fundamental
- Price
- EONR $0.39
- PPBT $2.20
- Analyst Decision
- EONR Strong Buy
- PPBT Strong Buy
- Analyst Count
- EONR 1
- PPBT 1
- Target Price
- EONR $4.50
- PPBT $33.00
- AVG Volume (30 Days)
- EONR 317.4K
- PPBT 285.3K
- Earning Date
- EONR 05-23-2025
- PPBT 05-23-2025
- Dividend Yield
- EONR N/A
- PPBT N/A
- EPS Growth
- EONR N/A
- PPBT N/A
- EPS
- EONR N/A
- PPBT N/A
- Revenue
- EONR $20,269,293.00
- PPBT N/A
- Revenue This Year
- EONR $46.94
- PPBT N/A
- Revenue Next Year
- EONR $64.38
- PPBT N/A
- P/E Ratio
- EONR N/A
- PPBT N/A
- Revenue Growth
- EONR N/A
- PPBT N/A
- 52 Week Low
- EONR $0.35
- PPBT $2.00
- 52 Week High
- EONR $3.15
- PPBT $20.60
- Technical
- Relative Strength Index (RSI)
- EONR N/A
- PPBT 35.17
- Support Level
- EONR N/A
- PPBT $2.16
- Resistance Level
- EONR N/A
- PPBT $2.41
- Average True Range (ATR)
- EONR 0.00
- PPBT 0.21
- MACD
- EONR 0.00
- PPBT -0.01
- Stochastic Oscillator
- EONR 0.00
- PPBT 16.48
About EONR EON RESOURCES INC
EON Resources Inc is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. Its current focus is as an upstream energy company producing oil and gas properties in the Permian Basin.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.